Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

(2012) N. Vande Casteele et al.   Journal of Crohns & Colitis

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

(2012) Hidetoshi Takahashi et al.   JOURNAL OF DERMATOLOGY

Etanercept Concentration in Patients with Rheumatoid Arthritis and Its Potential Influence on Treatment Decisions: A Pilot Study

(2012) CLAIRE IMMEDIATO DAÏEN et al.   JOURNAL OF RHEUMATOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction

(2011) J.H.O. Hoffmann et al.   BRITISH JOURNAL OF DERMATOLOGY

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

(2011) N Vande Casteele et al.   GUT

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis

(2011) Motoaki Hoshino et al.   Modern Rheumatology

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

(2010) A. W. R. van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

(2010) Lidian L. A. Lecluse et al.   ARCHIVES OF DERMATOLOGY

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis

(2010) A. Fonia et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

(2010) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

(2010) Esra ADIŞEN et al.   JOURNAL OF DERMATOLOGY

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

(2009) Nádia Emi Aikawa et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

(2008) Lucien Aarden et al.   CURRENT OPINION IN IMMUNOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY